Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases

American Journal of Pathology

Volumn 174, Issue 5, 2009, Pages 1921-1930

  Neuwirt, Hannes ^a   Puhr, Martin ^a   Santer, Frédéric R ^a   Susani, Martin ^b   Doppler, Wolfgang ^a   Marcias, Gemma ^a   Rauch, Veronika ^a   Brugger, Maria ^a   Hobisch, Alfred ^c   Kenner, Lukas ^b,d   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c General Hospital Feldkirch   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DOXYCYCLINE; INTERLEUKIN 6; MESSENGER RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; CCND1 PROTEIN, HUMAN; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DNA MICROARRAY; ENZYME REGULATION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; DOWN REGULATION; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

AGED; ANDROGENS; BLOTTING, WESTERN; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 65649134366     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080751     Document Type: Article

References (47)

1. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI: Pathological and molecular aspects of prostate cancer. Lancet 2003, 361:955-964 (Pubitemid 36332115)
2. Culig Z, Steiner H, Bartsch G, Hobisch A: Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005, 95:497-505 (Pubitemid 41420180)
3. Larsen L, Ropke C: Suppressors of cytokine signalling: SOCS. Apmis 2002, 110:833-844 (Pubitemid 36177279)
4. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 2005, 24:6699-6708 (Pubitemid 41486800)
5. Lee TL, Yeh J, Van Waes C, Chen Z: Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin- 6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006, 5:8-19
6. Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W: Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 2004, 112:1003-1009 (Pubitemid 39507006)
7. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D, Heiniger A, Torres A: The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 2004, 89:42-48 (Pubitemid 38165854)
8. Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C, Luger TA, Böhm M: Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004, 123:737-745 (Pubitemid 39281615)
9. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z: Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 2006, 169:2199-2208
10. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z: Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer 2007, 14:1007-1019
11. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, Schmidt WE, Tannapfel A: Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut 2007, 56:1047-1053 (Pubitemid 47123231)
12. Albanesi C, Fairchild HR, Madonna S, Scarponi C, De Pita O, Leung DY, Howell MD: IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007, 179:984-992
13. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC: Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008, 68:85-91
14. Gonzales-Moreno O, Calvo A, Joshi BH, Abasolo I, Leland P, Wang Z, Montuenga L, Puri RK, Green JE: Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer 2005, 114:870-878 (Pubitemid 40504466)
15. Park Y, Shon SK, Kim A, Kim KI, Yang Y, Cho DH, Lee MS, Lim JS: SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem Biophys Res Commun 2007, 363:361-367 (Pubitemid 47484341)
16. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z: Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001, 7:2941-2948 (Pubitemid 32911405)
17. Haffner MC, Petridou B, Beyrat JP, Révillion F, Müller-Holzner E, Daxenbichler G, Marth C, Doppler W: Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007, 7:136 (Pubitemid 47272230)
18. Savinainen KJ, Saramäki OR, Linja MJ, Bratt O, Tammela TLJ, Isola JJ, Visakorpi T: Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002, 160:339-345 (Pubitemid 34052294)
19. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, Idarraga MH, Kenner L, Wagner EF: Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA: 2008, 105:10525-10530
20. Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin- Lanneree S, Kenner L, Kerenyl Yahiaoui S, Gouilleux-Gruart V, Gondry J, Benit L, Dusanter-Fourt I, Lassoued K, Valent P, Morrigl R, Gouilleaux F: Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 2008, 112:2463-2473
21. Zitzmann K, Brand S, De Toni EN, Baehs S, Goke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ: SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 2007, 67:5025-5032 (Pubitemid 46910213)
22. Zhou H, Miki R, Eeva M, Fike FM, Seligson D, Yang L, Yoshimura A, Teitell MA, Jamieson CA, Cacalano NA: Reciprocal regulation of SOCS1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res 2007, 13:2344-2353 (Pubitemid 46698583)
23. Tan SH, Nevalainen MT: Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008, 15:367-390
24. Das S, Roth CP, Wasson LM, Vishwanatha JK: Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 2007, 67:1550-1564 (Pubitemid 47536154)
25. Giri D, Ozen M, Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001, 159:2159-2165 (Pubitemid 33104270)
26. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995, 45:542-549
27. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z: Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003, 162:655-663 (Pubitemid 36267872)
28. Flowers LO, Subramaniam PS, Johnson HM: A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 2005, 24:2114-2120 (Pubitemid 40516206)
29. Spiotto MT and Chung TD: STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000, 42:88-98 (Pubitemid 30056640)
30. Kreis S, Munz GA, Haan S, Heinrich PC, Behrmann I: Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res 2007, 5:1331-1341
31. Ogata Y, Osaki T, Naka T, Iwahori K, Furukawa M, Nagatomo I, Kijima T, Kumagai T, Yoshida M, Tachibana I, Kawase I: Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 2006, 8:817-825 (Pubitemid 44564837)
32. Karisen AE, Heding PE, Frobese H, Renn SG, Kruhoffer M, Orntoft TF, Darville M, Eizirik DL, Pociot F, Nerup J, Mandrup-Poulsen T, Billestrup N: Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB-regulated proapoptotic pathways. Diabetologia 2004, 47:1998-2011 (Pubitemid 40110212)
33. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, Chang CS: Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 2003, 123:654-661 (Pubitemid 37468062)
34. Hatirnaz O, Ure U, Ar C, Akyerli C, Soysal T, Ferhanoglu B, Ozcelik T, Ozbek U: The SOCS-1 gene methylation in chronic myeloid leukemia patients. Am J Hematol 2007, 82:729-730 (Pubitemid 47221655)
35. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubreuil P, de Sepulveda P: The tumor suppressor activity of SOCS-1. Oncogene 2002, 21:4351-4362
36. Huang F-J, Steeg PS, Price JE, Chiu W-T, Chou P-C, Xie K, Sawaya R, Huang S: Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 2008, 68:9634-9642
37. Shen L, Evel-Kabler K, Strube R, Chen SY: Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nature Biotechnol 2004, 22:1546-1553 (Pubitemid 40039457)
38. Tuxhorn JA, McAlhany SJ, Jang F, Dang TD, Rowley DR: Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002, 62:6021-6035
39. Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C: Blockade of transforming growth factor-(beta) signaling in tumor-reactive CD8(+) T cells activates the antitumor response cycle. Mol Cancer Ther 2006, 5:1733-1743 (Pubitemid 44323241)
40. Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A: Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J 2008, 22:1258-1267
41. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT: PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006, 66:1329-1338 (Pubitemid 44384309)
42. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998, 58:4640-4645 (Pubitemid 28480629)
43. Lee SO, Lou W, Hou M, Onate SA, Gao AC: Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003, 22:7981-7988 (Pubitemid 37175863)
44. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettgrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ: Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 2008, 29:1148-1156
45. Craft N, Shostak Y, Carey M, Sawyers C: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999, 5:280-285 (Pubitemid 29124362)
46. Leong GM, Moverare S, Brce J, Doyle N, Sjögren K, Dahlman-Wright K, Gustafsson JA, Ho KK, Ohlsson C, Leung KC: Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology 2004, 145:5525-5531 (Pubitemid 39564592)
47. Matthews J, Almlöf T, Kietz S, Leers J, Gustafsson JA: Estrogen receptor-alpha regulates SOCS-3 expression in human breast cancer cells. Biochem Biophys Res Commun 2005, 335:168-174 (Pubitemid 41357463)